ATE451119T1 - Untereinheit-impfstoff gegen das respiratorische synzytialvirus - Google Patents

Untereinheit-impfstoff gegen das respiratorische synzytialvirus

Info

Publication number
ATE451119T1
ATE451119T1 AT04761567T AT04761567T ATE451119T1 AT E451119 T1 ATE451119 T1 AT E451119T1 AT 04761567 T AT04761567 T AT 04761567T AT 04761567 T AT04761567 T AT 04761567T AT E451119 T1 ATE451119 T1 AT E451119T1
Authority
AT
Austria
Prior art keywords
synzytial
subunity
virus
vaccine against
against respiratory
Prior art date
Application number
AT04761567T
Other languages
German (de)
English (en)
Inventor
Robert Anderson
Yan Huang
David Burt
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Application granted granted Critical
Publication of ATE451119T1 publication Critical patent/ATE451119T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04761567T 2003-07-15 2004-07-14 Untereinheit-impfstoff gegen das respiratorische synzytialvirus ATE451119T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48780403P 2003-07-15 2003-07-15
US56758604P 2004-05-03 2004-05-03
US10/888,805 US7368537B2 (en) 2003-07-15 2004-07-09 Subunit vaccine against respiratory syncytial virus infection
PCT/CA2004/001007 WO2005007189A1 (en) 2003-07-15 2004-07-14 Subunit vaccine against respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
ATE451119T1 true ATE451119T1 (de) 2009-12-15

Family

ID=34084525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04761567T ATE451119T1 (de) 2003-07-15 2004-07-14 Untereinheit-impfstoff gegen das respiratorische synzytialvirus

Country Status (9)

Country Link
US (2) US7368537B2 (cg-RX-API-DMAC7.html)
EP (2) EP1651264B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007505033A (cg-RX-API-DMAC7.html)
AT (1) ATE451119T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004257363A1 (cg-RX-API-DMAC7.html)
CA (1) CA2532164A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024542D1 (cg-RX-API-DMAC7.html)
ES (1) ES2337901T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005007189A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002245636B2 (en) * 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
CA2543080C (en) 2003-10-22 2019-01-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
US20060229233A1 (en) * 2004-06-25 2006-10-12 Id Biomedical Corporation Compositions and methods for treating neurological disorders
HUE029258T2 (en) 2007-12-24 2017-02-28 Id Biomedical Corp Quebec Recombinant rsv antigens
CA2731194A1 (en) * 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
MA33449B1 (fr) 2009-06-24 2012-07-03 Glaxosmithkline Biolog Sa Antigènes recombinants du vrs
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP4218800A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US8846056B2 (en) * 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
US8730396B2 (en) * 2010-06-23 2014-05-20 MindTree Limited Capturing events of interest by spatio-temporal video analysis
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
SI2590676T1 (sl) * 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
ES2586580T3 (es) * 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
DK2590675T3 (en) 2010-07-07 2018-10-29 Artificial Cell Tech Inc ANTI-ANTI-COMPOSITIONS AND PROCEDURES FOR RESPIRATORY SYNCYTIAL VIRUS
SI3970742T1 (sl) * 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo RNA, ki kodira imunogen
WO2012030901A1 (en) * 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2012205315B2 (en) * 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
RU2456020C1 (ru) * 2011-03-30 2012-07-20 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой
KR101998431B1 (ko) * 2011-04-26 2019-07-09 몰레큘라 익스프레스 인코포레이티드 리포솜 제제
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
BR112016002354A2 (pt) 2013-08-05 2017-09-12 Glaxosmithkline Biologicals Sa composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
US9415101B2 (en) * 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR101695518B1 (ko) * 2014-09-30 2017-01-12 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 범용 백신
EP3373961A4 (en) * 2015-11-10 2019-07-31 Ohio State Innovation Foundation METHODS AND COMPOSITIONS ASSOCIATED WITH ACCELERATED HUMORAL AFFINITY
EP3694548A4 (en) 2017-10-13 2021-10-20 Trellis Bioscience, LLC CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
HUP9901577A3 (en) * 1995-09-18 2000-03-28 Lowell Georg H Cote St Luc Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US5848152A (en) 1995-09-26 1998-12-08 Motorola, Inc. Communication device having interchangeable faceplates and active keypad cover
CA2302833C (en) 1997-09-19 2007-05-08 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
CA2400468C (en) * 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
AU2002245636B2 (en) * 2001-03-09 2004-10-14 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection

Also Published As

Publication number Publication date
AU2004257363A1 (en) 2005-01-27
EP1651264B1 (en) 2009-12-09
WO2005007189A1 (en) 2005-01-27
EP1651264A1 (en) 2006-05-03
US20080226673A1 (en) 2008-09-18
ES2337901T3 (es) 2010-04-30
CA2532164A1 (en) 2005-01-27
EP2204188A1 (en) 2010-07-07
US7368537B2 (en) 2008-05-06
DE602004024542D1 (de) 2010-01-21
US20050042230A1 (en) 2005-02-24
JP2007505033A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
MA27047A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae.
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
NO20034410D0 (no) Vaksinesammensetning
WO2004030608A3 (en) Nanoemulsion vaccines
ATE485056T1 (de) Verbesserte impfstoffe
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
DK1427444T3 (da) West-nil-vaccine
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
EP1423141A4 (en) VACCINE
NO20033882L (no) Vaksine
NO20052149D0 (no) Vaksine.
DE60130998D1 (de) Ribavirin-enthaltende vakzine
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
WO2004091524A3 (en) Respiratory virus vaccines
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
NO20054070D0 (no) 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties